A putative anti-inflammatory role for TRPM8 in irritable bowel syndrome-An exploratory study

Madusha Peiris*, Zsa Zsa R. M. Weerts, Rubina Aktar, Ad A. M. Masclee, Ashley Blackshaw, Daniel Keszthelyi

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


Background Chronic and recurring pain is a characteristic symptom in irritable bowel syndrome (IBS). Altered signaling between immune cells and sensory neurons within the gut may promote generation of pain symptoms. As transient receptor potential melastatin 8 (TRPM8) agonists, such as L-menthol in peppermint oil, have shown to attenuate IBS pain symptoms, we began investigating potential molecular mechanisms.

Methods Colonic biopsy tissues were collected from patients with IBS and controls, in two separate cohorts. Immunohistochemistry was performed to identify TRPM8 localization. Quantitative PCR was performed to measure mucosal mRNA levels of TRPM8. In addition, functional experiments with the TRPM8 agonist icilin were performed ex vivo to examine cytokine release from biopsies. Daily diaries were collected to ascertain pain symptoms.

Results In biopsy tissue from IBS patients, we showed that TRPM8 immunoreactivity is colocalized with immune cells predominantly of the dendritic cell lineage, in close approximation to nerve endings, and TRPM8 protein and mRNA expression was increased in IBS patients compared to controls (p < 0.001). TRPM8 mRNA expression showed a significant positive association with abdominal pain scores (p = 0.015). Treatment of IBS patient biopsies with icilin reduced release of inflammatory cytokines IL-1 beta, IL-6, and TNF-alpha (p < 0.05).

Conclusions and inferences These data indicate TRPM8 may have important anti-inflammatory properties and by this virtue can impact neuro-immune disease mechanisms in IBS.

Original languageEnglish
Article number14170
Number of pages8
JournalNeurogastroenterology and Motility
Issue number9
Early online date19 Jun 2021
Publication statusPublished - Sept 2021


  • IBS
  • TRPV1

Cite this